PMID- 34993216
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220108
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 8
DP  - 2021
TI  - Alterations in the Gut Microbiota and Hepatitis-B-Virus Infection in Southern 
      Chinese Patients With Coexisting Non-Alcoholic Fatty Liver Disease and Type-2 
      Diabetes Mellitus.
PG  - 805029
LID - 10.3389/fmed.2021.805029 [doi]
LID - 805029
AB  - Background: Hepatitis B virus (HBV) infection has been reported to affect the 
      bacterial characteristics in the host. We aimed to elucidate the compositional 
      and functional characteristics of the microbiota in southern Chinese patients 
      with coexistent HBV infection, non-alcoholic fatty liver disease (NAFLD), and 
      type-2 diabetes mellitus (T2DM). Methods: Healthy controls (HCs) and patients 
      with coexistent NAFLD and T2DM were enrolled. Patients were divided into two 
      groups: N1 (without HBV infection) and N2 (with HBV infection). Stool samples 
      were collected for 16s RNA gene sequencing and untargeted metabolomics analysis. 
      Results: Bacterial diversity was decreased in the N2 group. There was a 
      significantly lower abundance of bacteria of Faecalibacterium, Gemmiger, and 
      Clostridium_XIVA genera, but a higher abundance of Megamonas and 
      Phascolarctobacterium genera in the N2 group. Compared with the N1 group, the 
      abundance of Gemmiger species was even lower, and alterations in the abundance of 
      Phascolarctobacterium and Clostridium_XIVA genera only occurred in the N2 group. 
      There were significantly different fecal metabolic features, which were enriched 
      in glucose and lipid metabolic pathways (e.g., fatty acid and glycerophospholipid 
      metabolism) between the N2 and HC groups. Metabolites in glycerophospholipid 
      metabolism, such as Sn-3-o-(geranylgeranyl)glycerol1-phosphate, were even higher 
      in the N2 group than in the N1 group. The decreased Faecalibacterium and Gemmiger 
      contributed to the increased level of Sn-3-o-(geranylgeranyl) 
      glycerol1-phosphate, palmitoylcarnitine, and serum triglycerides. 
      Clostridium_XIVA species were positively correlated to 15(s)-hpete. Megamonas 
      species were positively correlated with the serum level of glucose indirectly. 
      Conclusions: The distinct gut-microbiome profile associated with HBV infection 
      has a role in lipid metabolism and glucose metabolism in patients with coexistent 
      NAFLD and T2DM. Clinical Trial Registration: www.ClinicalTrials.gov, identifier: 
      NCT03525769.
CI  - Copyright (c) 2021 Han, Huang, Ji, Zhou, Chen and Hou.
FAU - Han, Weijia
AU  - Han W
AD  - Department of Liver Disease Center, Shenzhen Hospital, Southern Medical 
      University, Shenzhen, China.
AD  - Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern 
      Medical University, Guangzhou, China.
FAU - Huang, Chunyang
AU  - Huang C
AD  - Second Department of Liver Disease Center, Beijing Youan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Ji, Yali
AU  - Ji Y
AD  - Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern 
      Medical University, Guangzhou, China.
FAU - Zhou, Ling
AU  - Zhou L
AD  - Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern 
      Medical University, Guangzhou, China.
FAU - Chen, Jinjun
AU  - Chen J
AD  - Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern 
      Medical University, Guangzhou, China.
AD  - Hepatology Unit, Zengcheng Branch, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
AD  - Chinese (Acute on) Chronic Liver Failure Consortium (Ch-CLIF.C), Shanghai, China.
FAU - Hou, Jinlin
AU  - Hou J
AD  - Department of Liver Disease Center, Shenzhen Hospital, Southern Medical 
      University, Shenzhen, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03525769
PT  - Journal Article
DEP - 20211221
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC8724037
OTO - NOTNLM
OT  - HBV
OT  - NAFLD
OT  - hepatitis B virus
OT  - metabolome
OT  - microbiota
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/01/08 06:00
MHDA- 2022/01/08 06:01
PMCR- 2021/12/21
CRDT- 2022/01/07 06:29
PHST- 2021/10/29 00:00 [received]
PHST- 2021/11/23 00:00 [accepted]
PHST- 2022/01/07 06:29 [entrez]
PHST- 2022/01/08 06:00 [pubmed]
PHST- 2022/01/08 06:01 [medline]
PHST- 2021/12/21 00:00 [pmc-release]
AID - 10.3389/fmed.2021.805029 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2021 Dec 21;8:805029. doi: 10.3389/fmed.2021.805029. 
      eCollection 2021.